http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2017269-A8

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d9adaa7e7ce01ce8020f5c721aba10
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-36
filingDate 1999-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_072a2fd995a3ac5fb3238696c7a9d9ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c363a50aa57e7d1398e52e5cb41f1fa7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd5146aa7cda3ce3ffe78dba53fc67f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f45df7ee72ec97cd67550cec150ee8fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40bc01dc4ac23ab015727561170f1ab2
publicationDate 2009-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2017269-A8
titleOfInvention A pharmaceutical composition comprising form II crystalline Ritonavir and a preparation thereof
abstract This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.
priorityDate 1998-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID392622
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128681033
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226398153
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505741

Total number of triples: 35.